Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITAS
2022-502483-21-00Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Insomnia comparing Tasipimidine with Placebo (2 arms). Primary endpoints: Wake after sleep onset (WASO) Day 1-2 combined and Latency to persistent sleep (LPS) Day 1-2 combined. Started Jul 2023; status: completed.
02
Drugs
tasipimidine
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2022-502483-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502483-21-00.